Inovio Q1 net loss narrows to $19.7M; BLA submission for INO-3107 on track for mid-2025

INOVIO PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$0.51 revenue$65,343

Net loss narrowed to $19.7M ($0.51/share) from $30.5M ($1.31) in Q1 2024.
Cash and short-term investments $68.4M as of Mar 31, 2025, down from $94.1M at Dec 31, 2024.
On track to begin rolling BLA submission for INO-3107 (RRP) in mid-2025; FDA acceptance targeted by year-end.
DMAb Phase 1 trial: 100% of participants (24/24) at week 72 maintained antibody levels; no anti-drug antibodies.
R&D expenses decreased to $16.1M from $20.9M; net cash burn guidance ~$22M for Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.